Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Stock Information for SciSparc Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SciSparc Ltd.

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.